• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Drug news & perspectives

    Drug news & perspectives

    JournalISSN 0214-0934eISSN 2013-0139

    年发文量

    研究主题

    论文(995)

    排序
    1Targeting Amyloid Precursor Protein Secretases: Alzheimer's Disease and Beyond.
    J. Ganjei

    This review evaluates past and present clinical trials, as well as the current preclinical drug candidates focused on treating Alzheimer's disease (AD), in order to better assess the trends in AD drug discovery in context with specific drug mechanisms. The author begins by presenting a summary of the results of over 160 clinical trials targeted at AD, of which 52% have either failed to meet clinical endpoints or stalled (defined for the purpose of this review as no clinical or publicly mentioned progress for at least 3 years). The author postulates that many of the current clinical approaches fail to sufficiently regulate the amyloid cascade that includes, but is not limited to, the production of soluble β-amyloid precursor protein, β-amyloid and/or amyloid precursor protein intracellular domain and including activation of the tau cascade, ultimately translating to no improvement in cognitive function. To support this argument, the author compares clinical results and peer-reviewed opinions to postulate that appropriately focused multifunctional or dual pathway drugs could make the optimal candidate(s) for further investigations.

    2010引用:2
    引用
    AI阅读
    加入学术空间
    2The Promise of Imaging Biomarkers.
    J. Trueta

    In this white paper, Thomson Reuters provides a snapshot of the imaging biomarkers at use in research and development, and the clinic; examines key technical and commercialization challenges; and identifies promising avenues for progress in the field with insight from experts from industry and academia.

    2010引用:1
    引用
    AI阅读
    加入学术空间
    3The Angiotensin AT2 Receptor in Inflammation
    Franziska Rompe,Thomas Unger,Ulrike Muscha Steckelings

    Chronic inflammation is increasingly regarded not just as a consequence of a continuous infectious hazard, but also as an integral part of many noninfectious diseases such as autoimmune disorders, diabetes or cardiovascular disease. Thus, it is not surprising that some hormonal systems, like the renin-angiotensin system (RAS), which were originally described in the context of cardiovascular disease have also turned out to be major regulators of the inflammatory response. This review focuses on the role of the RAS in inflammation, with particular emphasis on the role of the angiotensin AT(2) receptor. While the proinflammatory features of the angiotensin AT(1) receptor are well established, most current evidence supports an anti-inflammatory role for AT(2) receptor. However, data on this receptor in inflammation are still rather sparse and are somewhat controversial. This article will discuss the principal mechanisms of AT(2) receptor-coupled interference with proinflammatory pathways as well as data derived from animal models of specific diseases. Finally, it will give a brief outlook into new possibilities in AT(2) receptor research and in the potential utilization of AT(2) receptor stimulation as a novel pharmacological concept in anti-inflammation.

    2010引用:44
    引用
    AI阅读
    加入学术空间
    4Cixutumumab
    E.K. Rowinsky, J.D. Schwartz, N. Zojwalla, H. Youssoufian, Floyd E. Fox, P. Pultar, Dale L. Ludwig
    2010
    引用
    AI阅读
    加入学术空间
    5Recent Developments in Metabotropic Glutamate Receptors As Novel Drug Targets
    M. J. O'Neill,M. J. Fell,K. A. Svensson,J. M. Witkin,S. N. Mitchell

    Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system, activating ionotropic (iGlu) and metabotropic (mGlu) glutamate receptors. Targeting iGlu receptors has proven difficult, as these receptors play such a critical role in fast synaptic transmission. In recent years, there has been a switch in the focus of the pharmaceutical industry to target mGlu receptors, as these receptors have a more modulatory role in the brain. Eight subtypes of the G protein-coupled mGlu receptors have been cloned and classified into three groups according to their second messenger association, sequence homology and agonist selectivity. Group I (mGlu(1) and mGlu(5)) receptors are positively coupled to phosphatidylinositol (PO hydrolysis, while group II (mGlu(2) and mGlu(3)) and group III (mGlu(4), mGlu(6), mGlu(7) and mGlu(8)) receptors are negatively coupled to adenylate cyclase and thought to act as presynaptic autoreceptors, regulating glutamate transmission. There has been rapid progress in understanding the biology of mGlu receptors and their function in the central nervous system (CNS), and the field now has highly potent and selective ligands for many of the mGlu receptor subtypes. Pharmacological tools include both orthosteric and allosteric agonists and antagonists. These molecules have been explored across a range of CNS conditions, the findings of which will be discussed briefly in this review. Recently, some of the most promising molecules have progressed into clinical trials (mGlu(2/3) receptor agonists for the treatment of anxiety and schizophrenia and mGlu(5) receptor antagonists for acute migraine and L-DOPA-induced dyskinesia) and achieved proof of concept. These encouraging results suggest mGlu receptors as novel drug targets with application in a range of psychiatric and neurological conditions.

    2010引用:24
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 995 篇论文

    高被引作者

    作者引用发文
    Tadafumi Kato5201
    Wojciech Danysz4951
    G Quack4951
    Chris G Parsons4951
    Eric L. Gustafson4241
    Suke Wang4241
    Romano G39919
    Herbert Herzog3771
    Gen-Shui Zhang3631
    Chen Min-Sheng3631

    高产作者

    作者引用发文
    B Spilker6422
    Romano G39919
    Sheila A. Doggrell27812
    Db Jack7712
    D Jack20911
    W Sneader24011
    A. I. Graul20111
    Alan M. Palmer24310
    Norman Peter19910
    Ernest K. J. Pauwels34310

    相关期刊

    Medicinal Research Reviews
    Current medicinal chemistry
    Current opinion in investigational drugs (London, England : 2000)
    Current drug targets
    IDrugs : the investigational drugs journal
    Neurotherapeutics
    Expert opinion on therapeutic patents
    Current Opinion in Pharmacology
    Frontiers in Medicinal Chemistry - Online